La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Calumet a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Calumet..

Calumet (NASDAQ:CLMT) Azioni, Catena delle Opzioni

CALUMET INC

Calumet

Calumet Specialty Prods

Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.

Calumet Inc

Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) ("Calumet" or the "Company") announced today that it has extended its Shreveport terminal asset financing arrangement with Stonebriar Commercial Finance LLC ("Stonebriar"). This transaction increases the assigned value of these terminal assets to $120 million and will provide $80 million of proceeds to Calumet, the difference between the new value of the assets and the remaining $40 million balance on the prior schedule. The previous sale leaseback agreement originally valued these assets at $70 million, which were scheduled to be repurchased in February 2027. This transaction carries a cost of capital of 10.75%, and net proceeds will be used to reduce Calumet's outstanding 11.00% Senior Notes due 2026 ("2026 Notes"). Further, Calumet has delivered a notice for a partial redemption of $80 million aggregate principal amount of its outstanding 2026 Notes at a redemption price of par, plus accrued and unpaid interest to, but not including, the redemption date of August 12, 2025.&nbsp; &nbsp;&nbsp;

News

CLMT

Calumet Extends Shreveport Terminal Financing Arrangement With Stonebriar, Unlocks $80M Proceeds Via $120M Asset Revaluation

WIIM

AREC

BANL

CGBS

CIVI

CTRA

EQNR

FANG

GPRE

HUSA

ICON

IMPP

INDO

KLXE

MARPS

NINE

RCON

SHEL

SKYQ

TRGP

USEG

VTLE

Shares of energy stocks are trading higher following Israel's strikes on Iran, which have raised oil prices amid potential disruptions in production.

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Overweight and lowers the price target from $23 to $21.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $21

BofA Securities analyst Conor Fitzpatrick initiated coverage on Calumet, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Buy rating <a href="https://www.benzinga.com/quote/CLMT/analyst-ratings" target="_blank" rel="noreferrer noopener">and a price forecast of $15.</a>
The analyst noted that Calumet&#8217;s Montana Renewables unit is advancing its MaxSAF project to boost sustainable aviation fuel output from ~40 million to over 250 million gallons annually, aiming to tap into stronger pricing and subsidy benefits over renewable diesel and petroleum.
According to Fitzpatrick, the expansion is expected to nearly double EBITDA from 2025 to 2027 and is supported by interest-free DOE loans, reducing execution risk.
Also Read: <a href="https://www.benzinga.com//node/45384593">Why Is Aemetis Stock Trading Higher On Tuesday?</a>
Management plans to monetize the asset to cut debt, which could bring parent leverage below 2.5x through deconsolidation and repayment.
The analyst pointed out that Calumet underperformed during the ramp-up of its biofuels unit, Montana Renewables, due to margin pressure, but recent developments may shift momentum.
Reports suggest that the Environmental Protection Agency is preparing to increase demand for Renewable Identification Numbers, or RINs, beginning in 2026, following lobbying from oil and agricultural interests. Meanwhile, California is in the process of re-approving measures to boost demand for Low Carbon Fuel Standard, or LCFS credits.
Prices for RINs have approximately doubled since December 2024, and the analyst expects them to remain within a favorable range, with some upside potential as regulatory developments advance.
A recovery in demand for LCFS credits is also anticipated, which would support higher margins.
For the investment thesis to materialize, the analyst notes that the company must demonstrate margin recovery in financial performance, achieve meaningful volume growth at MRL, and make tangible progress toward monetizing MRL and reducing overall leverage.
Price Action: CLMT shares are trading higher by 5.84% to $13.89 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45365162/cathie-wood-makes-bullish-move-on-baidu-ark-adds-30k-shares-amid-china-us-trade-thaw" target="_blank" rel="noreferrer noopener">Cathie Wood Makes Bullish Move On Baidu: Ark Adds 30K+ Shares Amid China-US Trade Thaw</a></li>
</ul>
Image by Phongphan via Shutterstock

Analyst Color

Equities

Initiation

Markets

Movers

Trading Ideas

General

Calumet Renewables Expansion Is Unlocking Value: Analyst

B of A Securities analyst Conor Fitzpatrick initiates coverage on Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Buy rating and announces Price Target of $15.

B of A Securities Initiates Coverage On Calumet with Buy Rating, Announces Price Target of $15

Calumet Specialty Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) reported quarterly losses of $(1.87) per share which missed the analyst consensus estimate of $(0.57) by 228.07 percent. This is a 266.67 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $993.90 million which beat the analyst consensus estimate of $891.44 million by 11.49 percent. This is a 1.20 percent decrease over sales of $1.01 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Calumet Specialty Prods Q1 EPS $(1.87) Misses $(0.57) Estimate, Sales $993.90M Beat $891.44M Estimate

<h3>Companies Reporting Before The Bell</h3>
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $120.47 million. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $28.07 million. 
• Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $214.44 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $21.60 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is projected to report quarterly loss at $0.06 per share on revenue of $180.69 million. 
• TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $650.27 million. 
• EchoStar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) is projected to report quarterly loss at $0.80 per share on revenue of $3.87 billion. 
• Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) is projected to report quarterly loss at $0.05 per share on revenue of $285.18 million. 
• Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) is projected to report quarterly earnings at $1.65 per share on revenue of $310.79 million. 
• Veren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $719.90 million. 
• TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $432.72 million. 
• Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $652.63 million. 
• Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is expected to report quarterly earnings at $0.59 per share on revenue of $261.77 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $57.10 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is projected to report earnings for its first quarter. 
• Plains All American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $14.00 billion. 
• Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) is expected to report quarterly earnings at $0.95 per share on revenue of $10.31 billion. 
• Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report earnings for its first quarter. 
• uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) is estimated to report quarterly loss at $0.96 per share on revenue of $6.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is projected to report earnings for its first quarter. 
• Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) is likely to report quarterly loss at $0.01 per share on revenue of $23.68 million. 
• Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $54.50 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is projected to report quarterly loss at $0.06 per share on revenue of $47.69 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is likely to report quarterly loss at $0.14 per share on revenue of $1.87 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $105.16 million. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $1.45 million. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is projected to report quarterly loss at $0.05 per share on revenue of $29.22 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is projected to report quarterly loss at $0.52 per share on revenue of $918.50 million. 
• Koppers Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is projected to report quarterly earnings at $0.56 per share on revenue of $488.00 million. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is likely to report quarterly loss at $0.27 per share on revenue of $6.63 million. 
• Associated Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AC#NYSE">AC</a>) is estimated to report quarterly loss at $0.47 per share on revenue of $5.33 billion. 
• Federal Agricultural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGM#NYSE">AGM</a>) is estimated to report earnings for its first quarter. 
• Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) is estimated to report quarterly loss at $0.90 per share on revenue of $10.73 million. 
• First Trust Switzerland AlphaDEX Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSZ#NASDAQ">FSZ</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $171.64 million. 
• Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) is likely to report quarterly earnings at $0.69 per share on revenue of $817.58 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is projected to report earnings for its first quarter. 
• AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) is estimated to report quarterly earnings at $0.81 per share on revenue of $567.23 million. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is likely to report quarterly loss at $0.17 per share on revenue of $586.15 million. 
• Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) is likely to report quarterly loss at $0.06 per share on revenue of $559.61 million. 
• Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $468.00 million. 
• BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $208.66 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is expected to report quarterly loss at $0.13 per share on revenue of $22.28 million. 
• Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $12.97 billion. 
<h3>Companies Reporting After The Bell</h3>
• Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is estimated to report earnings for its first quarter. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is projected to report earnings for its first quarter. 
• Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) is expected to report earnings for its first quarter. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is projected to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMCX

ANIK

ANIP

CMCT

DCBO

DIBS

EMBC

ESNT

GOGO

INUV

KYMR

LOGC

MSGM

NSPR

OCGN

ORLA

PAGP

QURE

ROAD

RPID

SATS

SLVM

STRW

STWD

TIXT

TXNM

ULBI

WULF

Earnings Scheduled For May 9, 2025

Calumet Specialty Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is gearing up to announce its quarterly earnings on Friday, 2025-05-09. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Calumet Specialty Prods will report an earnings per share (EPS) of $-0.52.
Anticipation surrounds Calumet Specialty Prods's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.10 in the last quarter, leading to a 0.0% drop in the share price on the following day.
Here's a look at Calumet Specialty Prods's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.37</td>
<td>-0.34</td>
<td>-0.55</td>
<td>-0.67</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.47</td>
<td>-1.18</td>
<td>-0.48</td>
<td>-0.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>10.0%</td>
<td>16.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746723660_0.png" alt="eps graph" />
<h3>Tracking Calumet Specialty Prods's Stock Performance</h3>
Shares of Calumet Specialty Prods were trading at $11.35 as of May 07. Over the last 52-week period, shares are down 26.49%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/CLMT/earnings">To track all earnings releases for Calumet Specialty Prods visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Calumet Specialty Prods's Earnings

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Buy and lowers the price target from $16 to $14.

Goldman Sachs Maintains Buy on Calumet, Lowers Price Target to $14

DINO

HAFN

LBRT

LTBR

Shares of energy stocks are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Overweight and lowers the price target from $28 to $23.

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $23

ACDC

CSAN

Shares of energy companies are trading lower possibly amid ongoing weakness after crude levels dropped to 2021 levels following OPEC+'s decision to accelerate production hikes. Also, the industry may be declining due to global tensions related to US-China retaliatory tariffs.

Jim Carter and Dan Sheets have informed the Board of their decision not to seek re-election and to retire at the end of their terms following the Annual Meeting.
&nbsp;

Management

Calumet Reveals Intention To Nominate Julio Quintana And Karen Narwold To Board; Wasserstein Debt Opportunities Expresses Support

Calumet shares are trading higher following a UBS ratings upgrade from Sell to Neutral and amid overall strength in the oil and gas sector.

GEVO

MPLX

NCSM

NEHC

OPAL

Shares of oil and gas companies are trading higher amid weakness in the dollar after the US launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting the demand outlook.

UBS analyst Manav Gupta upgrades Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Sell to Neutral and lowers the price target from $15 to $12.

Upgrades

UBS Upgrades Calumet to Neutral, Lowers Price Target to $12

Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Overweight and lowers the price target from $29 to $28.

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $28

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) with a Buy and maintains $33 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Calumet, Maintains $33 Price Target

Calumet Specialty Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.73) by 35.62 percent. This is a 20.34 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $949.50 million which beat the analyst consensus estimate of $921.76 million by 3.01 percent. This is a 2.76 percent decrease over sales of $976.50 million the same period last year.

Calumet Specialty Prods Q4 2024 GAAP EPS $(0.47) Beats $(0.73) Estimate, Sales $949.50M Beat $921.76M Estimate

Calumet Streamlines Specialties Business With $110M Sale Of Royal Purple Industrial Line, Retains Texas Production Facility

Commodities

Press Releases

Calumet to Attend Wolfe Research Conference

Calumet Announces Intention to Nominate Julio Quintana and Karen Narwold to Board of Directors; and Wasserstein Debt Opportunities Expresses Support

Calumet Announces Closing of Sale of Assets Related to Industrial Portion of its Royal Purple® Business

Calumet, Inc. to Release First Quarter 2025 Earnings on May 9, 2025

Calumet Reports First Quarter 2025 Results

Calumet to Participate in June 2025 Investor Conferences

Calumet, Inc. to Release Second Quarter 2025 Earnings on August 8, 2025

Calumet Announces $120 million Extension with Stonebriar

Calumet to Participate in September 2025 Investor Conferences

Eldridge Closes $120 Million Lease With Calumet

Aemetis

Clean Energy Fuels

Cosan

CVR Energy

HF Sinclair

Delek US Hldgs

FutureFuel

Gevo

Green Plains

Comstock

Marathon Petroleum Corporation Common Stock

Marathon Petroleum

OPAL Fuels

Par Pacific Hldgs

PBF Energy

Phillips 66

REX American Resources

Sky Quarry

Sunoco LP Common Units representing limited partner interests

Sunoco

Verde Clean Fuels, Inc. - Class A Common Stock

Verde Clean Fuels

Valero Energy

World Kinect

Wells Fargo

B of A Securities

Goldman Sachs

HC Wainwright & Co.

Comments

Calumet

Calumet (CLMT) Opzioni

Calumet (NASDAQ:CLMT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO